The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033 moving forward with ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.86, ...

The CHERISH trial has been stopped following the analysis and will be able to move to the SHINE open-label extension study to receive Spinraza. Meanwhile the FDA has said it plans to make a fast ...

But Spinraza costs $750,000 in the first year of ... oral administration method will give it a competitive edge. The FDA approved Evrysdi for the treatment of spinal muscular atrophy (SMA ...

Ionis Pharmaceuticals IONS recently announced positive top-line results from the phase III ESSENCE study evaluating its ...

The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood test for early Alzheimer's detection in adults aged 55 and older showing symptoms. It analyzes ...

The Food and Drug Administration (FDA) announced Friday it had cleared a new test to help diagnose adults with Alzheimer’s disease, the first diagnostic tool that uses a blood draw to check for ...

The first-ever blood test to detect Alzheimer’s disease has been cleared by the U.S. Food and Drug Administration (FDA). In a Friday press release, the agency announced its approval of the first ...

Previously, the only FDA-approved methods for detecting amyloid were invasive tests of spinal fluid or expensive PET scans. The blood test identifies a sticky brain plaque that is a key marker for ...

The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is ...